$PCRX News

Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact

Pacira (PCRX) Q2 2026 Earnings Call Transcript

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function

Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ...

Pacira Biosciences (NASDAQ:PCRX) Beats Q2 EPS Estimates, Misses on Revenue and Cuts Outlook

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est

Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process